T1	p 198 238	zoster ( HZ ) and postherpetic neuralgia
T2	p 262 297	individuals > or =60 years of age .
T3	p 476 548	subjects > or =50 years of age . Subjects with a negative history for HZ
T4	p 639 642	1:2
T5	p 646 672	age ( 50 to 59 years and >
T6	p 676 687	=60 years )
T7	i 98 164	refrigerator-stable formulation of Zostavax . The vaccine Zostavax
T8	i 357 414	refrigerator-stable formulation ( Zostavax refrigerated )
T9	i 433 472	current formulation ( Zostavax frozen )
T10	i 599 623	formulation . Enrollment
T11	i 686 687	)
T12	i 1572 1586	injection-site
T13	i 1905 1913	Zostavax
T14	o 198 204	zoster
T15	o 690 696	Safety
T16	o 741 790	Varicella-zoster virus ( VZV ) antibody responses
T17	o 810 822	glycoprotein
T18	o 902 943	VZV antibody geometric mean titer ( GMT ;
T19	o 959 1004	VZV antibody geometric mean rise ( GMR ; days
T20	o 1013 1014	)
T21	o 1017 1089	and the incidence of vaccine-related serious adverse experiences ( AEs )
T22	o 1186 1190	GMTs
T23	o 1249 1316	estimated GMT ratio ( refrigerated formulation/frozen formulation )
T24	o 1424 1451	vaccine-related serious AEs
T25	o 1492 1498	safety
T26	o 1557 1590	frequencies of injection-site AEs
T27	o 1747 1759	systemic AEs
T28	o 1932 1938	safety